Heparin, Low-Molecular-Weight: Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.Heparin Antagonists: Coagulant substances inhibiting the anticoagulant action of heparin.Heparin Lyase: An enzyme of the isomerase class that catalyzes the eliminative cleavage of polysaccharides containing 1,4-linked D-glucuronate or L-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-D-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-D-gluc-4-enuronosyl groups at their non-reducing ends. (From Enzyme Nomenclature, 1992) EC 184.108.40.206.Heparin Cofactor II: A sulfated plasma protein with a MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.Anticoagulants: Agents that prevent clotting.Antithrombin III: A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.Antithrombins: Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.Partial Thromboplastin Time: The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.Glycosaminoglycans: Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine or N-acetylgalactosamine.Enoxaparin: Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)Whole Blood Coagulation Time: The time required by whole blood to produce a visible clot.Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed)Protamines: A group of simple proteins that yield basic amino acids on hydrolysis and that occur combined with nucleic acid in the sperm of fish. Protamines contain very few kinds of amino acids. Protamine sulfate combines with heparin to form a stable inactive complex; it is used to neutralize the anticoagulant action of heparin in the treatment of heparin overdose. (From Merck Index, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p692)Factor Xa: Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.Platelet Factor 4: A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.Hirudins: Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.Thrombin: An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.Fibrinolytic Agents: Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.Blood Coagulation: The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.Polysaccharide-Lyases: A group of carbon-oxygen lyases. These enzymes catalyze the breakage of a carbon-oxygen bond in polysaccharides leading to an unsaturated product and the elimination of an alcohol. EC 4.2.2.Hemorrhage: Bleeding or escape of blood from a vessel.Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).Blood Coagulation Tests: Laboratory tests for evaluating the individual's clotting mechanism.Chromatography, Affinity: A chromatographic technique that utilizes the ability of biological molecules to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Heparinoids: Heparin derivatives. The term has also been used more loosely to include naturally occurring and synthetic highly-sulphated polysaccharides of similar structure. Heparinoid preparations have been used for a wide range of applications including as anticoagulants and anti-inflammatories and they have been claimed to have hypolipidemic properties. (From Martindale, The Extra Pharmacopoeia, 30th, p232)Hirudin Therapy: Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.Oligosaccharides: Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form.Chondroitin Sulfates: Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.Protein Binding: The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.Thrombin Time: Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin.Binding Sites: The parts of a macromolecule that directly participate in its specific combination with another molecule.Disaccharides: Oligosaccharides containing two monosaccharide units linked by a glycosidic bond.Kinetics: The rate dynamics in chemical or physical systems.Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.Thrombocytopenia: A subnormal level of BLOOD PLATELETS.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Pentosan Sulfuric Polyester: A sulfated pentosyl polysaccharide with heparin-like properties.Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Sulfates: Inorganic salts of sulfuric acid.PolysaccharidesPulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.Pipecolic AcidsInjections, Subcutaneous: Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.Iduronic Acid: Component of dermatan sulfate. Differs in configuration from glucuronic acid only at the C-5 position.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Fibroblast Growth Factor 1: A 17-kDa single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. It binds to HEPARIN, which potentiates its biological activity and protects it from proteolysis. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages, and also has chemotactic and mitogenic activities. It was originally named acidic fibroblast growth factor based upon its chemical properties and to distinguish it from basic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 2).Antithrombin Proteins: An endogenous family of proteins belonging to the serpin superfamily that neutralizes the action of thrombin. Six naturally occurring antithrombins have been identified and are designated by Roman numerals I to VI. Of these, Antithrombin I (see FIBRIN) and ANTITHROMBIN III appear to be of major importance.Carbohydrate Sequence: The sequence of carbohydrates within POLYSACCHARIDES; GLYCOPROTEINS; and GLYCOLIPIDS.Sulfuric Acids: Inorganic and organic derivatives of sulfuric acid (H2SO4). The salts and esters of sulfuric acid are known as SULFATES and SULFURIC ACID ESTERS respectively.SepharoseSwine: Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.Molecular Weight: The sum of the weight of all the atoms in a molecule.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.Factor X: Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder.Fibrinopeptide A: Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Lipoprotein Lipase: An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 220.127.116.11.Serine Proteinase Inhibitors: Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.Flavobacterium: A genus of gram-negative, aerobic, rod-shaped bacteria widely distributed in SOIL and WATER. Its organisms are also found in raw meats, MILK and other FOOD, hospital environments, and human clinical specimens. Some species are pathogenic in humans.Drug Contamination: The presence of organisms, or any foreign material that makes a drug preparation impure.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Fibroblast Growth Factor 2: A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).Time Factors: Elements of limited time intervals, contributing to particular results or situations.Uronic Acids: Acids derived from monosaccharides by the oxidation of the terminal (-CH2OH) group farthest removed from the carbonyl group to a (-COOH) group. (From Stedmans, 26th ed)Platelet Aggregation Inhibitors: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.Nitrous Acid: Nitrous acid (HNO2). A weak acid that exists only in solution. It can form water-soluble nitrites and stable esters. (From Merck Index, 11th ed)Chromatography, Gel: Chromatography on non-ionic gels without regard to the mechanism of solute discrimination.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.Prothrombin: A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.Binding, Competitive: The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements.Surface Plasmon Resonance: A biosensing technique in which biomolecules capable of binding to specific analytes or ligands are first immobilized on one side of a metallic film. Light is then focused on the opposite side of the film to excite the surface plasmons, that is, the oscillations of free electrons propagating along the film's surface. The refractive index of light reflecting off this surface is measured. When the immobilized biomolecules are bound by their ligands, an alteration in surface plasmons on the opposite side of the film is created which is directly proportional to the change in bound, or adsorbed, mass. Binding is measured by changes in the refractive index. The technique is used to study biomolecular interactions, such as antigen-antibody binding.Sulfotransferases: Enzymes which transfer sulfate groups to various acceptor molecules. They are involved in posttranslational sulfation of proteins and sulfate conjugation of exogenous chemicals and bile acids. EC 2.8.2.Disseminated Intravascular Coagulation: A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.Blood Coagulation Factors: Endogenous substances, usually proteins, that are involved in the blood coagulation process.Tissue Plasminogen Activator: A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases.Structure-Activity Relationship: The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.Platelet Glycoprotein GPIIb-IIIa Complex: Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.Streptokinase: Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.Chymases: A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Carbohydrate Conformation: The characteristic 3-dimensional shape of a carbohydrate.Venous Thromboembolism: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.Mast-Cell Sarcoma: A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.Hexadimethrine Bromide: A synthetic polymer which agglutinates red blood cells. It is used as a heparin antagonist.Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.Chlorates: Inorganic salts of chloric acid that contain the ClO3- ion.Electrophoresis, Polyacrylamide Gel: Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Prothrombin Time: Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Thrombolytic Therapy: Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Fibronectins: Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins.Antithrombin III Deficiency: An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).Dextrans: A group of glucose polymers made by certain bacteria. Dextrans are used therapeutically as plasma volume expanders and anticoagulants. They are also commonly used in biological experimentation and in industry for a wide variety of purposes.Platelet Aggregation: The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.Cricetinae: A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.Models, Molecular: Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Mast Cells: Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR.Chromatography, High Pressure Liquid: Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.Rabbits: The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.Protein Conformation: The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).Polymers: Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).Protease Nexins: Extracellular protease inhibitors that are secreted from FIBROBLASTS. They form a covalent complex with SERINE PROTEASES and can mediate their cellular internalization and degradation.Hemostasis: The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.CHO Cells: CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.Cell Adhesion: Adherence of cells to surfaces or to other cells.Recurrence: The return of a sign, symptom, or disease after a remission.Magnetic Resonance Spectroscopy: Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).Platelet Activation: A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.Postoperative Hemorrhage: Hemorrhage following any surgical procedure. It may be immediate or delayed and is not restricted to the surgical wound.Bleeding Time: Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.Factor IXa: Activated form of factor IX. This activation can take place via the intrinsic pathway by the action of factor XIa and calcium, or via the extrinsic pathway by the action of factor VIIa, thromboplastin, and calcium. Factor IXa serves to activate factor X to Xa by cleaving the arginyl-leucine peptide bond in factor X.Dextran Sulfate: Long-chain polymer of glucose containing 17-20% sulfur. It has been used as an anticoagulant and also has been shown to inhibit the binding of HIV-1 to CD4-POSITIVE T-LYMPHOCYTES. It is commonly used as both an experimental and clinical laboratory reagent and has been investigated for use as an antiviral agent, in the treatment of hypolipidemia, and for the prevention of free radical damage, among other applications.Receptors, Fibroblast Growth Factor: Specific molecular sites or structures on cell membranes that react with FIBROBLAST GROWTH FACTORS (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.Factor XIa: Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium.Fibrin Fibrinogen Degradation Products: Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.Fibroblast Growth Factors: A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family.Substrate Specificity: A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.Chemical Fractionation: Separation of a mixture in successive stages, each stage removing from the mixture some proportion of one of the substances, for example by differential solubility in water-solvent mixtures. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Complement C1 Inhibitor Protein: An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Blood Specimen Collection: The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.Thrombelastography: Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis.Glycoproteins: Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.Platelet Count: The number of PLATELETS per unit volume in a sample of venous BLOOD.Sulfuric Acid Esters: Organic esters of sulfuric acid.Chromatography, Ion Exchange: Separation technique in which the stationary phase consists of ion exchange resins. The resins contain loosely held small ions that easily exchange places with other small ions of like charge present in solutions washed over the resins.Laminin: Large, noncollagenous glycoprotein with antigenic properties. It is localized in the basement membrane lamina lucida and functions to bind epithelial cells to the basement membrane. Evidence suggests that the protein plays a role in tumor invasion.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Chondroitin: A mucopolysaccharide constituent of chondrin. (Grant & Hackh's Chemical Dictionary, 5th ed)Extracellular Matrix: A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere.Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Thrombospondins: A family of related, adhesive glycoproteins which are synthesized, secreted, and incorporated into the extracellular matrix of a variety of cells, including alpha granules of platelets following thrombin activation and endothelial cells. They interact with a number of BLOOD COAGULATION FACTORS and anticoagulant factors. Five distinct forms have been identified, thrombospondin 1, -2, -3, -4, and cartilage oligomeric matrix protein (COMP). They are involved in cell adhesion, platelet aggregation, cell proliferation, angiogenesis, tumor metastasis, VASCULAR SMOOTH MUSCLE growth, and tissue repair.Serpins: A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.Muscle, Smooth, Vascular: The nonstriated involuntary muscle tissue of blood vessels.Angioplasty, Balloon, Coronary: Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.Catheters, Indwelling: Catheters designed to be left within an organ or passage for an extended period of time.Fat Emulsions, Intravenous: Emulsions of fats or lipids used primarily in parenteral feeding.Hydrogen-Ion Concentration: The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH = log 1/2[1/(H+)], where (H+) is the hydrogen ion concentration in gram equivalents per liter of solution. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Protein Structure, Tertiary: The level of protein structure in which combinations of secondary protein structures (alpha helices, beta sheets, loop regions, and motifs) pack together to form folded shapes called domains. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Small proteins usually consist of only one domain but larger proteins may contain a number of domains connected by segments of polypeptide chain which lack regular secondary structure.CitratesGlucuronidaseCardiopulmonary Bypass: Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs.Serine Endopeptidases: Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.Collagen: A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH).Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.Ancrod: An enzyme fraction from the venom of the Malayan pit viper, Agkistrodon rhodostoma. It catalyzes the hydrolysis of a number of amino acid esters and a limited proteolysis of fibrinogen. It is used clinically to produce controlled defibrination in patients requiring anticoagulant therapy. EC 3.4.21.-.Blood Proteins: Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.Lipase: An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. It is produced by glands on the tongue and by the pancreas and initiates the digestion of dietary fats. (From Dorland, 27th ed) EC 18.104.22.168.Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.Electrophoresis, Paper: Electrophoresis in which paper is used as the diffusion medium. This technique is confined almost entirely to separations of small molecules such as amino acids, peptides, and nucleotides, and relatively high voltages are nearly always used.Peptides: Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.Chondroitinases and Chondroitin Lyases: Enzymes which catalyze the elimination of glucuronate residues from chondroitin A,B, and C or which catalyze the hydrolysis of sulfate groups of the 2-acetamido-2-deoxy-D-galactose 6-sulfate units of chondroitin sulfate. EC 4.2.2.-.DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.Osmolar Concentration: The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent.Immunoglobulin Fab Fragments: Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.Periodic Acid: A strong oxidizing agent.Coated Materials, Biocompatible: Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself.Catheterization, Central Venous: Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein.Protease Inhibitors: Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).Renal Dialysis: Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.Infusions, Parenteral: The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.SulfatasesEdetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.Amino Acids, DiaminoAcute Disease: Disease having a short and relatively severe course.Blood Coagulation Disorders: Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.p-Dimethylaminoazobenzene: A reagent used mainly to induce experimental liver cancer. According to the Fourth Annual Report on Carcinogens (NTP 85-002, p. 89) published in 1985, this compound "may reasonably be anticipated to be a carcinogen." (Merck, 11th ed)Growth Substances: Signal molecules that are involved in the control of cell growth and differentiation.Sodium Chloride: A ubiquitous sodium salt that is commonly used to season food.Hyaluronic Acid: A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Capparaceae: A plant family of the order Capparales, subclass Dilleniidae, class Magnoliopsida, that are mostly herbs and shrubs growing in warm arid regions. Several produce GLUCOSINOLATES.Sagittal Sinus Thrombosis: Formation or presence of a blood clot (THROMBUS) in the SUPERIOR SAGITTAL SINUS or the inferior sagittal sinus. Sagittal sinus thrombosis can result from infections, hematological disorders, CRANIOCEREBRAL TRAUMA; and NEUROSURGICAL PROCEDURES. Clinical features are primarily related to the increased intracranial pressure causing HEADACHE; NAUSEA; and VOMITING. Severe cases can evolve to SEIZURES or COMA.Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.Receptors, Cell Surface: Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)P-Selectin: Cell adhesion molecule and CD antigen that mediates the adhesion of neutrophils and monocytes to activated platelets and endothelial cells.Fibrinolysin: A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.Chromatography: Techniques used to separate mixtures of substances based on differences in the relative affinities of the substances for mobile and stationary phases. A mobile phase (fluid or gas) passes through a column containing a stationary phase of porous solid or liquid coated on a solid support. Usage is both analytical for small amounts and preparative for bulk amounts.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Protein C: A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.Casein Kinases: A group of protein-serine-threonine kinases that was originally identified as being responsible for the PHOSPHORYLATION of CASEINS. They are ubiquitous enzymes that have a preference for acidic proteins. Casein kinases play a role in SIGNAL TRANSDUCTION by phosphorylating a variety of regulatory cytoplasmic and regulatory nuclear proteins.
List of Knights of the Baltimore City College
One example is the grouped analysis of several tannic acids that accumulate in ageing Scotch whisky in oak barrels. The grouped ... One example is a sensor sensitive to heparin. Other receptors are sensitive not to a specific molecule but to a molecular ... and forms of metal detection by so-called complexones which are traditional pH indicators retrofitted with molecular groups ...
It is specifically used in heparin overdose, in low molecular weight heparin overdose, and to reverse the effects of heparin ... While there is no evidence of harm from using during pregnancy it has not been well studied in this group. Protamine works by ... Dosage for heparin reversal is 1.0 -to- 1.5 mg protamine sulfate IV for every 100 IU of active heparin, not to exceed 50 mg. ... It is a highly cationic peptide that binds to either heparin or low molecular weight heparin (LMWH) to form a stable ion pair, ...
Damage-associated molecular pattern
Examples of non-protein DAMPs include ATP, uric acid, heparin sulfate and DNA. The chromatin-associated protein high-mobility ... Lotze, Michael T; Tracey, Kevin J (2005). "High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal". ... Protein DAMPs include intracellular proteins, such as heat-shock proteins or HMGB1 (high-mobility group box 1), and proteins ... Damage Associated Molecular Pattern Molecules Group at University of Pittsburgh Lotze, Michael T; Deisseroth, Albert; ...
It has been suggested that a GAG should qualify as heparin only if its content of N-sulfate groups largely exceeds that of N- ... Compare this to heparin where IdoA(2S)-GlcNS(6S) makes up 85% of heparins from beef lung and about 75% of those from porcine ... These are often collectively called the "heparin interactome" or "heparin-binding proteins", because they are isolated by ... acetyl groups and the concentration of O-sulfate groups exceeds those of N-sulfate. Not shown below are the rare disaccharides ...
Bone morphogenetic protein 3
heparan sulfate)-glucosamine 3-sulfotransferase 2
Other names in common use include glucose 3-O-nontransferable, heparin sulfate D-glucose 3-O-nontransferable, and formalism/ ... This enzyme belongs to the family of transferences, specifically the transformer, which transfer sulfur-containing groups. The ... "Multiple lifeforms of heparin sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human ... isomerism 2 (3-OAT-2, HST). This enzyme participates in heparin sulfate biosynthesis and glycogen structures - biosynthesis 1. ...
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins ... The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society ... Dalteparin is not superior to unfractionated heparin in preventing blood clots. Heparins are cleared by the kidneys, but ... Clinical Trials Group (2011). "Dalteparin versus unfractionated heparin in critically ill patients". doi:10.1056/NEJMoa1014475 ...
Robert J. Linhardt
Linhardt's group has been working on a collaboration to bioengineer Heparin from E. coli. This is in part a response to the ... Linhardt Group Page School of Science Faculty Profile School of Engineering Faculty Profile. ... "Outbreak of adverse reactions associated with contaminated heparin". N Engl J Med. 359: 2674-84. doi:10.1056/NEJMoa0806450. PMC ... outbreak of adverse heparin reactions in 2007. This work helped earn him a spot in the Scientific American 10, for the 10 ...
Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins. Reviparin is a low molecular weight ... Its structure is characterized, for the most part, by a group of 2-O-sulfo-α-lidopyranosuronic acid. The average molecular ... 2005). "Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute ... Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). ...
Thrombocytopenia was more often seen in the tirofiban + heparin group (1.5%) than in the heparin control group (0.8%). This ... withdrawal of heparin. The following side effects were noted under treatment with tirofiban and heparin (and aspirin, if ... Thrombocytopenia: Discontinue tirofiban and heparin. Bleeding is the most commonly reported adverse reaction. Tirofiban has ...
Bemiparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH). Like semuloparin, bemiparin is ... Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, ... Planès, A. (2003). "Review of bemiparin sodium - a new second-generation low molecular weight heparin and its applications in ... "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and ...
ADAM VA Cooperative Group Trial - 73451 VA patients screened with no known hx of aneurysm; Age 50-79; AAA 4.0-5.4 cm; similar ... Conclusion: Intraoperative heparin, given before aortic cross clamping, is an important prophylaxic against perioperative MI in ... ADAM VA Cooperative Study Group". J Vasc Surg. 20 (2): 296-303. PMID 8040955. Thompson JF; Mullee MA; Bell PR; et al. (July ... Joint Vascular Research Group Trial - 284 patients; Study the relationship between intraoperative intravenous heparinization, ...
The usual ratio of heparinized saline is 5,000 units of heparin per 1,000 ml of 0.9% sodium chloride. The heparin is removed ... Eurosets Sorin Group Haemonetics Fresenius Davol Boehringer laboratories American Association of Blood Banks International ... Many of the newest autotransfusion machines are programmable to provide separation of blood into three groups; red cells, ... by the loss of one or more units of blood and may be particularly advantageous for use in cases involving rare blood groups, ...
This latter group may have more significant side effects especially if taken for a long period of time. Pacemakers are often ... Anticoagulant medications such as warfarin and heparins, and anti-platelet drugs such as aspirin can reduce the risk of ... Several groups of drugs slow conduction through the heart, without actually preventing an arrhythmia. These drugs can be used ... Heart arrhythmia, also known as cardiac dysrhythmia or irregular heartbeat, is a group of conditions in which the heartbeat is ...
Clearly, heparin-coated blood oxygenators exhibit some advantages over non-coated oxygenators. Some hospitals use heparin- ... atrial fibrillation compared to identical uncoated controls Overall clinical results were favorable in both groups Statistics ... Operations which involve uncoated CPB circuits require a high dose of systemic heparin. Although the effects of heparin are ... Systemic heparin does not completely prevent clotting or the activation of complement, neutrophils, and monocytes, which are ...
Heparan sulfate 6-O-endosulfatases, such as SULF2, selectively remove 6-O-sulfate groups from heparan sulfate. This activity ... Heparan sulfate proteoglycans (HSPGs) act as coreceptors for numerous heparin-binding growth factors and cytokines and are ... selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1". BMC Biochemistry. 7: 2. ... "Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans". The Journal of ...
ATC code B01
B01AB Heparin group. B01AB01 Heparin. B01AB02 Antithrombin III. B01AB04 Dalteparin. B01AB05 Enoxaparin. B01AB06 ... B01AB51 Heparin, combinations. B01AC Platelet aggregation inhibitors excluding heparin. B01AC01 Ditazole. B01AC02 ... Subgroup B01 is part of the anatomical group B Blood and blood forming organs. ...
Sulf2 inhibited both pre- and post-binding of VEGF165, FGF-1, and SDF-1, a HS-binding chemokine, to both heparin and HS. ... Heparan sulfate 6-O-endo-sulfatases, such as SULF1, selectively remove 6-O-sulfate groups from heparan sulfate. This activity ... In addition, Sulf1 expression is required to suppress sustained activation of ERK1/2 and c-met by the heparin binding growth ... The lack of Sulf1 expression also augments heparin binding-epidermal growth factor (HB-EGF) response by way of greater EGF ...
This practice is opposed by a variety of human rights groups, including Organs Watch, a group established by medical ... coagulation must be prevented with large amounts of anti-coagulation agents such as heparin. Several ethical and procedural ... Greenwood Publishing Group. p. 11. ISBN 0-313-33542-7. Legendre, Ch; Kreis, H. (November 2010). "A Tribute to Jean Hamburger's ... His first patient died two days later, as the graft was incompatible with the recipient's blood group and was rejected. It was ...
"GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients ... The International Study Group". Lancet. 336 (8707): 71-5. doi:10.1016/0140-6736(90)91590-7. PMID 1975322. "GISSI-3: effects of ... The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) (Italian group for the study of the ... survival of Myocardial Infarction) is an influential cardiology research group founded as a collaboration between two Italian ...
... may be used as an anticoagulant when heparins (unfractionated or low-molecular-weight) are contraindicated because of ... differs by the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group ... Lubenow N, Eichler P, Lietz T, Greinacher A (2005). "Lepirudin in patients with heparin-induced thrombocytopenia - results of ... "Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced ...
Discovery and development of direct Xa inhibitors
Groups R2 and R3 were then substituted for various groups, which were all less potent than the hydrogen, so hydrogen was the ... Chains of natural heparin can vary from 5.000 to 40.000 Daltons. In the 1980s Low molecular weight heparin (LMWH) were ... During the SAR testing, R1 was defined as the most important group for potency. Pyrrolidinone was the first R1 functional group ... Afterwards, the silyl protecting group is removed and the resulting alcohol is replaced by an amino group which is then ...
Cell and tissue structures that have high concentrations of ionized sulfate and phosphate groups-such as the ground substance ... whilst heparin, with further N-sulfation, is strongly metachromatic. Therefore, toluidine blue will appear purple to red when ... Thus, hyaluronic acid, lacking sulphate groups and with only moderate charge density, causes slight metachromasia; chondroitin ... heparin mixtures, showing clearly that metachromasia, corresponding to the colour of stained cartilage, could be reproduced by ...
"Meet the winners! - BMJ Group Awards". Groupawards.bmj.com. Retrieved 2012-07-18. [permanent dead link] "CRASH-2 - Clinical ... "Detection of antiphospholipid antibodies based in heparin resistance.", and won the 2011 Research paper of the year at the BMJ ... guidelines development group for: "reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in ... Group for a paper entitled "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma ...
One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced ... Apart from the O-methyl group at the reducing end of the molecule, the identity and sequence of the five monomeric sugar units ... Within heparin and heparin sulfate this monomeric sequence is thought to form the high-affinity binding site for the anti- ... In contrast to heparin, fondaparinux does not inhibit thrombin. Fondaparinux is given subcutaneously daily. Clinically, it is ...
Contact between gorilla groups is rare, suggesting that transmission among gorilla groups is unlikely, and that outbreaks ... Other regulators of coagulation have also been tried including heparin in an effort to prevent disseminated intravascular ... International Publications Media Group. ISBN 978-1-63267-011-3. .. *. Ebola Virus: New Insights for the Healthcare Professional ... Boca Raton: CRC Press, Taylor & Francis Group. p. 444. ISBN 9781439884294. . Archived from the original on 29 April 2016.. ...
Fanning P.E.; Vannice M.A. (1993). "A DRIFTS study of the formation of surface groups on carbon by oxidation". Carbon. 31 (5): ... Since this activated carbon has no effect on blood clotting factors, heparin or most other anticoagulants  this allows a ... Sulfonic acid functional groups can be attached to activated carbon to give "starbons" which can be used to selectively ... Through the formation of a large number of basic and acidic groups on the surface of oxidized carbon to sorption and other ...
藥物過量 - 维基百科，自由的百科全书
White blood cell
Heparin is an anticoagulant that inhibits blood clotting and promotes the movement of white blood cells into an area. Basophils ... although those categories overlap and are often grouped as a pair. ... They excrete two chemicals that aid in the body's defenses: histamine and heparin. Histamine is responsible for widening blood ...
Anticoagulation appears to prevent miscarriage in pregnant women. In pregnancy, low molecular weight heparin and low-dose ... The network consists of a multidisciplinary group of physicians and investigators from around the world who are interested in ... Warfarin/Coumadin is not used during pregnancy because it can cross the placenta, unlike heparin, and is teratogenic. ... Antiphospholipid syndrome often requires treatment with anticoagulant medication such as heparin to reduce the risk of further ...
Items listed in bold indicate initially developed compounds of specific groups. #WHO-EM †Withdrawn drugs. ‡Veterinary use ... insights into heparin and collagen binding". J. Mol. Biol. 388 (2): 310-26. doi:10.1016/j.jmb.2009.03.026. PMID 19289127.. ... SODs were previously known as a group of metalloproteins with unknown function; for example, CuZnSOD was known as ...
Innate immune system
In general, phagocytes patrol the body searching for pathogens, but are also able to react to a group of highly specialized ... rich in histamine and heparin, along with various hormonal mediators and chemokines, or chemotactic cytokines into the ... Lotze MT, Tracey KJ (April 2005). "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal". Nature ...
In groups treated with the 0.3 mg dose at the primary efficacy endpoint, experienced a statistically significant result. ... Heparin-binding EGF-like growth factor (HB-EGF). *Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF)) ... results of the Pan-American Collaborative Retina Study Group at 12 months follow up". Retina. 28 (10): 1387-94. doi:10.1097/IAE ... age-related macular degeneration were randomly put into groups to receive either a placebo treatment or the designated 0.3 mg, ...
Ալերգիա - Վիքիպեդիա՝ ազատ հանրագիտարան
Often grouped under the labels of compassionate use, expanded access, or named patient supply, these programs are governed by ... Coagulation: anticoagulants, heparin, antiplatelet drugs, fibrinolytics, anti-hemophilic factors, haemostatic drugs. *HMG-CoA ... In the United States, ACT UP formed in the 1980s, and eventually formed its Treatment Action Group in part to pressure the US ... Drug use among elderly Americans has been studied; in a group of 2377 people with average age of 71 surveyed between 2005 and ...
Conditions caused by food allergies are classified into three groups according to the mechanism of the allergic response: ... 4 - preformed mediators (histamine, proteases, chemokines, heparin). 5 - granules. 6 - mast cell. 7 - newly formed mediators ( ... 2015). "Precautionary allergen labelling: perspectives from key stakeholder groups". Allergy. 70 (9): 1039-1051. doi:10.1111/ ...
IgE was simultaneously discovered in 1966 and 1967 by two independent groups: Kimishige Ishizaka and his wife Teruko ... heparin); 5 - granules; 6 - mast cell; 7 - newly formed mediators (prostaglandins, leukotrienes, thromboxanes, PAF) ... IL-5 and IL-13 as well as IL-33 which in turn activate group 2-innate lyphoid cells (ILC2, or natural helper cells). Basophils ...
Heparin group/. glycosaminoglycans/. (bind antithrombin). *Low molecular weight heparin *Bemiparin. *Certoparin. *Dalteparin ... As part of this effort, Lilly provided a group of physicians and bioethicists with a $1.8 million grant to form the Values, ... Clinicians should consider continuing prophylactic heparin at time of institution of Xigris infusion unless discontinuation of ... No significant differences between geriatric patients and younger patients regarding bleeding events in the drotrecogin group ...
Heparin (unfractionated heparin) and its derivatives low molecular weight heparin (LMWH) bind to a plasma cofactor, ... It is a serine endopeptidase (protease group S1, PA clan). Factor X is synthesized in the liver and requires vitamin K for its ... The affinity of unfractionated heparin and the various LMWHs for Factor Xa varies considerably. The efficacy of heparin-based ... This inactivation of Factor Xa by heparins is termed "indirect" since it relies on the presence of AT and not a direct ...
Anticoagulation can be achieved through several means including warfarin, heparin, dabigatran, rivaroxaban, edoxaban,[ ... "A Focus on Atrial Fibrillation in Scotland: A report by the Cross-Party Group in Heart Disease and Stroke" (PDF).. ... JCS Joint Working Group; Inoue, H; Atarashi, H; Kamakura, S; Koretsune, Y (August 2014). "Guidelines for Pharmacotherapy of ... Cochrane Heart Group (ed.). "Concomitant atrial fibrillation surgery for people undergoing cardiac surgery". Cochrane Database ...
Vertebral artery dissection
Treatment is usually with either antiplatelet drugs such as aspirin or with anticoagulants such as heparin or warfarin. ... The causes of vertebral artery dissection can be grouped under two main categories, spontaneous and traumatic. ... The two main treatments involve medication: anticoagulation (using heparin and warfarin) and antiplatelet drugs (usually ... heparin followed by warfarin) are equally effective in reducing the risk of further stroke or death. Anticoagulation is ...
Heparin group/. glycosaminoglycans/. (bind antithrombin). *Low molecular weight heparin *Bemiparin. *Certoparin. *Dalteparin ... causing a chemical reaction that turns salicylic acid's hydroxyl group into an ester group (R-OH → R-OCOCH3). This process ... Items listed in bold indicate initially developed compounds of specific groups. #WHO-EM †Withdrawn drugs. ‡Veterinary use ... The conjugate with the acetyl group intact is referred to as the acyl glucuronide; the deacetylated conjugate is the phenolic ...
ಆಸ್ಟಿಯೊಪೊರೋಸಿಸ್ - ವಿಕಿಪೀಡಿಯ
Raloxifene Study Group". Osteoporos Int. 10 (4): 330-6. doi:10.1007/s001980050236. PMID 10692984.. CS1 maint: Explicit use of ... Ruiz-Irastorza G, Khamashta MA, Hughes GR (2002). "Heparin and osteoporosis during pregnancy: 2002 update". Lupus. 11 (10): 680 ... Report of a WHO Study Group". World Health Organization technical report series. 843: 1-129. PMID 7941614.. ... Public Health and Environmental Exposure to Cadmium (PheeCad) Study Group". Lancet. 353 (9159): 1140-4. doi:10.1016/S0140-6736( ...
This group includes many of the most common cancers and include nearly all those in the breast, prostate, lung, pancreas and ... The use of heparin appears to improve survival and decrease the risk of blood clots.[needs update] ... Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. ... A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often form a mass or lump, but may be ...
... amino group of a lysine residue and a γ-carboxamide group of glutamine residue, creating an inter- or intramolecular bond that ... "Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to ... The catalytic mechanism for crosslinking in human tTG involves the thiol group from a Cys residue in the active site of tTG. ... Enzymatic interactions are formed between TG2 and its substrate proteins containing the glutamine donor and lysine donor groups ...
A group of antibodies can be called polyvalent (or unspecific) if they have affinity for various antigens or microorganisms ... "Blood Groups and Red Cell Antigens. NCBI Bethesda (MD): National Library of Medicine (US),.. ... The five different types of Fc regions allow antibodies to be grouped into five isotypes. Each Fc region of a particular ... Milland J, Sandrin MS (December 2006). "ABO blood group and related antigens, natural antibodies and transplantation". Tissue ...
ಹೃದಯಾಘಾತ - ವಿಕಿಪೀಡಿಯ
SOFA Study Group. (2006). "Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable ... "Heparin versus placebo for acute coronary syndromes". Cochrane Database Syst Rev (2): CD003462. doi:10.1002/14651858.CD003462. ... "Coronary calcium as a predictor of coronary events in four racial or ethnic groups". N. Engl. J. Med. 358 (13): 1336-45. doi ...
The nucleophilic sulfhydryl group allows cysteine to conjugate to other groups, e.g., in prenylation. Ubiquitin ligases ... based largely on the chemical parallel between its sulfhydryl group and the hydroxyl groups in the side chains of other polar ... "Vegetarian Resource Group.. *^ Martens, Jürgen; Offermanns, Heribert; Scherberich, Paul (1981). "Facile Synthesis of Racemic ... N-Acetyl-L-cysteine is a derivative of cysteine wherein an acetyl group is attached to the nitrogen atom. This compound is sold ...
위키백과:미번역 문서/의학 - 위키백과, 우리 모두의 백과사전
With heparin, risk of maternal haemorrhage and other complications are still increased, but heparins do not cross the placental ... low-dose haplotype group (A) and a high-dose haplotype group (B). VKORC1 polymorphisms explain why African Americans are on ... Heparin can also cause a prothrombotic condition, heparin-induced thrombocytopenia (an antibody-mediated decrease in platelet ... Warfarin is slower acting than the common anticoagulant heparin, though it has a number of advantages. Heparin must be given by ...
Heparin and warfarin are used to inhibit the formation and growth of existing thrombi, with the former used for acute ... Thrombi are classified in three major groups depending on the relative amount of platelets and red blood cells (RBCs). The ... Heparin works by binding to and activating the enzyme inhibitor antithrombin III, an enzyme that acts by inactivating thrombin ... Bleeding time with heparin and warfarin therapy can be measured with the partial thromboplastin time (PTT) and prothrombin time ...
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group....
A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. ... Low-molecular-weight heparin appears to be at least as effective and safe as standard, unfractionated heparin for the treatment ... 22 patients assigned to unfractionated heparin (7.1 percent) and 18 patients assigned to low-molecular-weight heparin (5.9 ... In the first eight days of treatment, 9 of 308 patients assigned to receive unfractionated heparin (2.9 percent) reached at ...
Heparin bridging after stroke linked with worse outcomes | Australian Doctor Group
One in five patients underwent bridging therapy with low-molecular-weight heparin. ... Bridging with low-molecular-weight heparin is associated with worse outcomes after stroke in patients with non-valvular atrial ... Heparin bridging after stroke linked with worse outcomes Even while waiting for warfarin to take effect, there is no reduction ... Bridging with low-molecular-weight heparin is associated with worse outcomes after stroke in patients with non-valvular atrial ...
FDA Finds Unidentified Substance in Heparin | Nolan Law Group
... s blood-thinning drug heparin. Read more here. ... Nolan Law Group Files Lawsuit on Behalf of the Parents of a 14- ... Heparin is produced from an enzyme in the mucous lining of pig intestines. The suspect lots of heparin were made beginning in ... FDA finds unidentified substance in Baxters blood-thinning drug heparin. *FDA Finds Contaminant in Baxters Recalled Heparin ... plant produced the heparin connected to the recent rash of serious allergic reactions. The suspect active ingredient in heparin ...
Clinical evaluation of Duraflo? II heparin treated extracorporeal circulation circuits (2nd version) the European working ...
Heparin-Induced Thrombocytopenia, or HIT - Warshauer Law Group Presentation | Warshauer Law Group
Warshauer Law Group N/a Warshauer Law Group Building 2740 Bert Adams Road NW Atlanta, GA 30339 (404) 892-4900 ... Heparin-Induced Thrombocytopenia, or HIT - Warshauer Law Group Presentation. Jul 16, 2015. ... Warshauer Law Group partner Frank Ilardi gave a broad presentation regarding Heparin-Induced Thrombocytopenia, or HIT,for short ... nationally known for his particular knowledge and expertise in cases involving blood clots and the adverse effects of Heparin. ...
Heparin Injury Lawsuit : Rottenstein Law Group LLP
High and low doses of Heparin could cause users a string of serious health risks. Learn more about the drug and how to file a ... RLG will also keep you up to date on any Heparin class action lawsuits, additional FDA Heparin warnings, and Heparin FDA recall ... The Heparin lawyers at the Rottenstein Law Group believe that obtaining legal satisfaction from those who harmed you shouldnt ... What Is Heparin and What Is It Prescribed For?. Heparin is a naturally occurring chemical in people. It is one of the oldest ...
Comparison of the oral delivery of three marketed Low Molecular Weight Heparins encapsulated in Nanoparticles | Debiopharm Group
Low molecular weight heparin for prevention of microvascular occlusion in digital replantation - Chen - 2013 - The Cochrane...
... and UFH groups but all data consistently showed that coagulability was reduced more in the UFH group than in the LMWH group. ... Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular ... Low molecular weight heparin for preventing vascular occlusion in replanted fingers or toes after amputation injuries ... Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. Yi-Chieh Chen, Ching-Chi Chi, ...
Impact of different Asian ethnic groups on correlation between heparin dose, activated clotting time and complications in...
Impact of different Asian ethnic groups on correlation between heparin dose, activated clotting time and complications in ... the mean total heparin dose was 6224 ± 1548 U, mean weight-adjusted heparin dose was 95 ± 30 U/kg, and mean ACT was 325 ± 95 s ... Impact of different Asian ethnic groups on correlation between heparin dose, activated clotting time and complications in ... were similar in the 3 ethnic groups. When the patients were divided based on ACT into 3 groups:, 250, 250-350 and, 350 seconds ...
Ordinary Heparin as Effective as Expensive Blood Thinner
Top selling expensive blood thinners are only as effective as injections of the blood thinner heparin to treat blood clots, ... Bombay Blood Group. Bombay blood group is a rare blood type in which the people have an H antigen deficiency. They can receive ... The latest, more expensive version of heparin is extracted from the original heparin and has smaller molecules which would mean ... Unfractionated heparin is the original blood thinner, derived from pig tissues, is mostly given intravenously in the hospital ...
Comparison of Unfractionated Heparin and Bivalirudin for Percutaneous Coronary Intervention for Stable Angina, Unstable Angina,...
unfractionated heparin. Description:. Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use ... Comparison of Unfractionated Heparin and Bivalirudin for Percutaneous Coronary Intervention for Stable Angina, Unstable Angina ... The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable ... Comparison of Unfractionated Heparin and Bivalirudin for Percutaneous Coronary Intervention for Stable Angina, Unstable Angina ...
Lipoprotein Lipase Mass and Activity in Plasma and Their Increase After Heparin Are Separate Parameters With Different...
Testing for the influence of hypertension in the control group was not possible because of the small number of hypertensive ... LPL activity in plasma before and after heparin injection are unrelated.15 16 17 The implication is that LPL in plasma is not ... Identification of a heparin-releasable lipoprotein lipase binding protein from endothelial cells. J Biol Chem. 1992;267:16517- ... Hence, heparin releases mainly active LPL. The four LPL parameters (mass and activity in plasma and their increase after ...
Do you give Heparin at your 6am med pass? | allnurses
Is it OK to give Heparin at 6am and then have the lab do the PT/INR at 7am? ... We give Heparin at 6am and then the Lab comes in at 7am. Some of these blood tests are PT/INR. ... We give Heparin at 6am and then the Lab comes in at 7am. Some of these blood tests are PT/INR. Is it OK to give Heparin at 6am ... have seen patients being weaned to warfarin from heparin....when PT/INR gets where they want it, the heparin is Dcd. ...
Top results for heparin - Trip Database
Patients in the bivalirudin group were subsequently randomly assigned to receive or not to receive (...) a post-PCI bivalirudin ... Unfractionated Heparin and Low-Molecular-Weight Heparin Unfractionated Heparin and Low-Molecular-Weight Heparin © 2013 ... Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU Nebulized Heparin for Adjunctive ... Heparin for the prevention of intraventricular hemorrhage in very preterm infants [Cochrane Protocol] Heparin for the ...
Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) - Full Text View - ClinicalTrials.gov
Group/Cohort Intervention/treatment Suspected HIT Those who are clinically suspected of having HIT will be enrolled in this ... Drug Information available for: Heparin Heparin sodium Genetic and Rare Diseases Information Center resources: Heparin-induced ... Calcium heparin. Heparin. Anticoagulants. Fibrinolytic Agents. Fibrin Modulating Agents. Molecular Mechanisms of ... Validating 4Ts for Heparin Induced Thrombocytopenia (HIT). The safety and scientific validity of this study is the ...
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services - Tabular View - ClinicalTrials.gov
Study Groups/Cohorts Not Provided. Publications * Not Provided. * Includes publications given by the data provider as well as ... Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services. The safety and scientific validity of ... In numerous clinical trials, LMWH has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term ... We wish to examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT) throughout the ...
Low molecular weight heparin use in primary care - BPJ 24 November 2009
... educational and continuing professional development programmes to medical practitioners and other health professional groups ... Low molecular weight heparin use in primary care. Enoxaparin (Clexane) is a low molecular weight heparin used in the treatment ... DHBNZ Safe and Quality Use of Medicines Group. Low molecular weight heparin treatment in renal impairment. 2008. Available from ... Heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia (HIT) is diagnosed when HIT antibodies are detected in ...
The efficacy and safety of enoxaparin vs unfractionated heparin in prevention of deep vein thrombosis in elective cancer...
What is the treatment of major hemorrhage in patients taking low-molecular-weight heparin (LMWH) for deep venous thrombosis ...
... is similar to heparin. However, the half-life of these agents is longer (4-6 h). As with heparin, fresh frozen pla... more ... The treatment of major hemorrhage associated with low-molecular-weight heparin (LMWH) ... Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar. 83-A(3):336-45. [Medline]. ... Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta- ...
RCSB PDB - 1TB6: 2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin Ternary Complex Structure Summary Page
RCSB PDB - 2ANT: THE 2.6 A STRUCTURE OF ANTITHROMBIN INDICATES A CONFORMATIONAL CHANGE AT THE HEPARIN BINDING SITE
Space Group: P 1 21 1. Unit Cell:. Length ( Å ). Angle ( ˚ ). ... and of the residues implicated in the binding of the heparin ... The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site.. Skinner, R., Abrahams, J.P. ... THE 2.6 A STRUCTURE OF ANTITHROMBIN INDICATES A CONFORMATIONAL CHANGE AT THE HEPARIN BINDING SITE. *DOI: 10.2210/pdb2ANT/pdb ... Areas of the extended amino terminus, unique to antithrombin and important in the binding of the glycosaminoglycan heparin, can ...
Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI) - Full Text View - ClinicalTrials.gov
Single Group Assignment. Masking:. None (Open Label). Primary Purpose:. Treatment. Official Title:. A Phase 2 Proof of Concept ... Heparin. Calcium heparin. Anticoagulants. Fibrinolytic Agents. Fibrin Modulating Agents. Molecular Mechanisms of ... Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI). The safety and scientific validity of this ... History of allergy to heparin (beef or pig), protamine, or salmon.. *History of chronic alcohol or drug abuse within the last ...
Heparin - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | RxWiki
Get up-to-date information on Heparin side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about ... Heparin Drug Class. Back to Top. Heparin is part of the drug class:. *. Heparin group. ... Heparin should not be administered into a muscle. If you must use heparin at home, your doctor will explain how this medicine ... Heparin falls into category C. There are no well-controlled studies that have been done in pregnant women. Heparin should be ...
ISRCTN - ISRCTN86885538: Taurolidine-citrate vs heparin as catheter lock solutions in paediatric patients
HBEGF - Heparin binding EGF like growth factor - Loxodonta africana (African elephant) - HBEGF gene & protein
It lists the nodes as they appear top-down in the taxonomic tree, with the more general grouping listed first.,p>,a href=/help ... Heparin binding EGF like growth factorImported. ,p>Information which has been imported from another database using automatic ... tr,G3T245,G3T245_LOXAF Heparin binding EGF like growth factor OS=Loxodonta africana OX=9785 GN=HBEGF PE=4 SV=1 ...
China Heparin Stopper, Heparin Stopper Manufacturers, Suppliers | Made-in-China.com
Select 2018 high quality Heparin Stopper products in best price from certified Chinese Medical manufacturers, Medical Supplies ... Group: All in Need. *Medical Device Regulatory Type: Type 2. *Colour: Yellow/Transparent ... Heparin Cap Heparin Cap Stopper Heparin Calcium Heparin Stopper Factory Wholesale Heparin Stopper More ... Sodium Heparin Tube Antibiotic Rubber Stopper Heparin Blood Collection Tube Heparin Lithium Snore Stopper Lithium Heparin Tube ...
Intravesical Instillation of Heparin Cocktail - Santa Ana, CA: Prestige Medical Group
Contact us at 949-339-1336 or visit us at 720 N. Tustin Ave, Suite 104, Santa Ana, CA 92705: Prestige Medical Group ... Prestige Medical Group. 720 N. Tustin Ave, Suite 104 Santa Ana, CA 92705. Phone: 949-339-1336 Fax: 949-825-7648 ... Prestige Medical Group, Santa Ana, CA. Phone (appointments): 949-339-1336 , Phone (general inquiries): 949-825-7650 Address: ...
What is the frequency and prevalence of heparin-induced thrombocytopenia (HIT)?
... has been reported in post-orthopedic surgery patients receiving up to 2 weeks of unfractionated heparin. HIT occurred in ... National Acute Chest Syndrome Study Group. N Engl J Med. 2000 Jun 22. 342(25):1855-65. [Medline]. ... encoded search term (What is the frequency and prevalence of heparin-induced thrombocytopenia (HIT)?) and What is the frequency ... What is the frequency and prevalence of heparin-induced thrombocytopenia (HIT)?. Updated: Jun 06, 2019 ...
Mythbusting: Heparin isn't beneficial for noninvasive management of NSTEMI
Introduction 0 The use of heparin for noninvasive management of non-ST elevation MI (NSTEMI) is one of the most deeply ... Group A = Aspirin only. Group B = Aspirin + heparin infusion. Group C = Aspirin + Nadroparin. ... low molecular-weight heparin, the low molecular-weight heparin group would probably do better because low molecular-weight ... 1990 RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men ...
Low Molecular Weight Heparin Market SWOT Analysis and innovations by Leading Key Players | Aspen, Sanofi-aventis, Pfizer |...
HTF MI published a new industry research that focuses on Low Molecular Weight Heparin (LMWHs) market and delivers in-depth ... On behalf of Pulsus group, we take immense pleasure in inviting all the participants from all over the world to attend the ... Low Molecular Weight Heparin Market SWOT Analysis and innovations by Leading Key Players , Aspen, Sanofi-aventis, Pfizer. ... HTF MI published a new industry research that focuses on Low Molecular Weight Heparin (LMWHs) market and delivers in-depth ...
AnticoagulantDeep-vein thromEffect of heparinMolecular Weight HeparinsPretreated with unfractionated heparinPulmonary embolismEnoxaparinPercutaneous coronary intHeparan sulfateCONCLUSIONSIntravenous heparinBlood clotsClinicalSulfateCatheter lockGlobal Heparin MarketPorcine mucosal heparinInjectionOutcomeEither low-moleculVenous2017Source of heparinSimilar to heparinKnown whether heparinThrombolytic therapyAnti-Xa activityIncidencePatencyPlaceboAbstractReceive heparinWidelyBivalirudinGlycoproteinDrug heparinGlycosaminoglycans5000 unitsRegimenThrombolysisThrombinPolysaccharidePlatelet aggregationMortalityLMWHsPreventionAcuteDoses
- The U.S. Food and Drug Administration (FDA) issued a drug safety communication regarding the labeling of the anticoagulant (blood thinner) Heparin . (rotlaw.com)
- The primary outcome measure of this study is the ability to reverse the anticoagulant effects of heparin (as measured by ACT) to the same extent as is known for protamine. (clinicaltrials.gov)
- Heparin is an anticoagulant or blood thinner produced by basophils and mast cells. (medgadget.com)
- Because of the unpredictable bioavailability of unfractionated heparin, frequent monitoring of the anticoagulant effect is necessary, with multiple dose adjustments. (bmj.com)
- Anticoagulant drugs such as aspirin or low molecular weight heparin may help women with recurrent miscarriage and such an underlying blood clotting problem. (cochrane.org)
- To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia. (cochrane.org)
- Each of these heparins was assayed for their molecular weight profile, AT affinity, USP potency, and anticoagulant/antiprotease profiles using standard laboratory methods. (frontiersin.org)
- Heparins derived from different tissues and/or species have been shown to differ in their degrees of sulfation and acetylation, molecular weight, and anticoagulant activity ( 6 - 9 ). (frontiersin.org)
- Heparin (HEP) and phosphorylcholine groups (PC) were grafted onto the polyurethane (PU) surface in order to improve biocompatibility and anticoagulant activity. (tut.fi)
- Heparin Mimicking Polymers are synthetic compounds that possess similar characteristics to heparin, that is it can be used clinically as an anticoagulant. (wikipedia.org)
- Heparin is widely used as a clinical anticoagulant however, it possesses drawbacks creating a need for synthetic heparin mimicking polymers. (wikipedia.org)
- Heparin, a highly sulfated form of HS, is widely used as anticoagulant drug worldwide. (rsc.org)
- 3 Heparin is a special form of HS, found within specialized granulated cells, having a higher level of sulfation, a higher IdoA content, and displaying prominent anticoagulant activity. (rsc.org)
- 6 A repeating trisulfated disaccharide sequence →4)IdoA2S(1→4)GlcNS6S(1→ corresponds to heparin's thrombin (or factor IIa, FIIa) binding site and facilitates the assembly of the ternary heparin-AT-FIIa complex required for heparin's global anticoagulant activity. (rsc.org)
- Heparin is called anticoagulant,Why? (somperi.com)
- Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. (cigna.com)
- 80 years, intracranial hemorrhage, transient neurologic deficits, sustained hypertension, major neurologic or systemic illness, recent major operation or tendency toward bleeding, receipt of anticoagulant therapy or necessity of such therapy for valvular heart disease, or known hypersensitivity to heparin. (acpjc.org)
- Heparin is a major anticoagulant with activity mediated primarily through its interaction with antithrombin (AT). (ahajournals.org)
- Early workers showed that a plasma protein was responsible for the anticoagulant effect of heparin. (ahajournals.org)
- A randomized phase II trial investigated whether adding CX-01, a low anticoagulant heparin derivative, to standard care improves outcomes in older patients with acute myeloid leukemia. (cancernetwork.com)
- Low-molecular-weight heparin appears to be at least as effective and safe as standard, unfractionated heparin for the treatment of deep-vein thrombosis, but only limited data are available on the use of low-molecular-weight heparin to treat acute symptomatic pulmonary embolism. (nih.gov)
- Deep vein thrombosis that appears most often as blood clots in the legs, is treated with injections of low-molecular weight heparin like Sanofi-Aventis' blockbuster Lovenox and Pfizer's Fragmin. (medindia.net)
- The efficacy and safety of enoxaparin vs unfractionated heparin in prevention of deep vein thrombosis in elective cancer surgery. (diva-portal.org)
- Research evaluating the treatment of deep vein thrombosis with low-molecular-weight heparin that had shown a reduction in mortality among patients with cancer led to renewed interest in the effect of these agents on the survival of such patients. (cmaj.ca)
- The purpose of this study was to find out the incidences of deep vein thrombosis, symptomatic, and fatal pulmonary embolism in Indian patients undergoing arthroplasties and to compare the effectiveness and safety of thromboprophylaxis with low molecular weight heparin versus aspirin plus intermittent pneumatic compression device. (nepjol.info)
- 300 patients (409 joints) were randomized into 2 groups and studied regarding the incidence of deep vein thrombosis, pulmonary embolism, safety of the thromboprophylaxis in regard to its efficacy. (nepjol.info)
- Heparin is also used to prevent blood clotting during dialysis, to prevent clotting of intravenous lines, to prevent unwanted blood clotting during open-heart surgery, and to treat deep vein thrombosis and pulmonary embolism. (medbroadcast.com)
Effect of heparin4
- Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. (emcrit.org)
- This review looked for randomised studies assessing the effect of heparin and related substances on preventing the onset of DKD. (cochrane.org)
- Although aPTT measurement has been the standard clinical approach to estimating the effect of heparin on thrombin inhibition, factors other than heparin affect aPTT. (onlinejacc.org)
- However, it is not known whether the protective effect of heparin is related to it's anticoagulative or anti-inflammatory effects. (lu.se)
Molecular Weight Heparins5
- The low-molecular-weight Heparins have many clinical advantages as compared to unfractionated Heparin. (orthogate.org)
- Unfractionated heparins (UFHs) and low molecular weight heparins (LMWHs) are polypharmacological agents, complex mixtures of molecules prepared from animal tissues. (rsc.org)
- Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. (hmdb.ca)
- BACKGROUND: Anticoagulation by the use of unfractionated or low molecular weight heparins (LMWHs) has been shown to lead to a survival advantage in cancer patients. (aacrjournals.org)
- Heparin and low molecular weight heparins are the most widely used anticoagulants in treatment of thromboembolic disease. (ahajournals.org)
Pretreated with unfractionated heparin1
- A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. (nih.gov)
- We randomly assigned 612 patients with symptomatic pulmonary embolism who did not require thrombolytic therapy or embolectomy to either subcutaneous low-molecular-weight heparin (tinzaparin) given once daily in a fixed dose or adjusted-dose, intravenous unfractionated heparin. (nih.gov)
- Under the conditions of this study, initial subcutaneous therapy with the low-molecular-weight heparin tinzaparin appeared to be as effective and safe as intravenous unfractionated heparin in patients with acute pulmonary embolism. (nih.gov)
- A porcine intestine or bovine lungs extract of heparin is used pharmaceutically in conditions such as DVT, pulmonary embolism, acute coronary syndrome, and atrial fibrillation to prevent clots. (medgadget.com)
- The rates of pulmonary embolism were 1% in the compression group and 1% in the heparin group, and there were no fatal pulmonary emboli. (nih.gov)
- Methods and Results- We performed a meta-analysis of all randomized trials comparing thrombolytic therapy with heparin in patients with acute pulmonary embolism. (ahajournals.org)
- Conclusions- Currently available data provide no evidence for a benefit of thrombolytic therapy compared with heparin for the initial treatment of unselected patients with acute pulmonary embolism. (ahajournals.org)
- The established treatment for acute pulmonary embolism is anticoagulation with unfractionated or low-molecular-weight heparin, 5 followed by at least 3 to 6 months of warfarin. (ahajournals.org)
- 15-17 Two of the meta-analyses pooled data from the same 9 randomized trials, yet they came to conflicting conclusions about the benefits of thrombolysis compared with heparin for the initial treatment of pulmonary embolism. (ahajournals.org)
- however, it remains underpowered to reliably detect a modest yet worthwhile reduction in pulmonary embolism or death with thrombolytic therapy compared with heparin. (ahajournals.org)
- To further clarify the role of thrombolysis for the treatment of pulmonary embolism, we performed an updated meta-analysis of all properly randomized trials comparing thrombolysis with heparin for the initial treatment of acute pulmonary embolism. (ahajournals.org)
- We attempted to identify all relevant published and unpublished randomized trials comparing thrombolysis with heparin for the initial treatment of pulmonary embolism. (ahajournals.org)
- The rates of pulmonary embolism were 0.67% in the Aspirin plus compression group and 0% in the heparin group, and there were no fatal pulmonary emboli. (nepjol.info)
- Enoxaparin (Clexane) is a low molecular weight heparin used in the treatment of acute coronary syndromes and in the treatment and prevention of thromboembolic disorders. (bpac.org.nz)
- Asia-Pacific Low Molecular Weight Heparin (LMWHs) (Thousands Units) and Revenue (Million USD) Market Split by Product Type such as Enoxaparin, Dalteparin, Tinzaparin & Fraxiparine. (medgadget.com)
- ORLANDO -- Acute myocardial infarction patients pretreated with anticoagulants before percutaneous coronary interventions appear to fare better with fondaparinux or enoxaparin than unfractionated heparin, researchers reported. (medpagetoday.com)
- The clinical impact of pretreatment with unfractionated heparin, enoxaparin, fondaparinux or no pretreatment before percutaneous coronary interventions has been unclear," Schiele said in his oral presentation. (medpagetoday.com)
- A third group of 270 patients (30%) received enoxaparin, and 299 (33%) were pretreated with fondaparinux. (medpagetoday.com)
- In patients with acute myocardial infarction submitted to percutaneous coronary interventions, pretreatment with enoxaparin or fondaparinux was safer and more effective than no pretreatment or pretreatment with unfractionated heparin. (medpagetoday.com)
- Currently, porcine mucosal heparin is the primary source of raw material for heparin worldwide, and the only source for the most widely used LMW heparin enoxaparin. (frontiersin.org)
- Enoxaparin is a low molecular weight heparin. (hmdb.ca)
- Tell patients who ask that in this study, a low-molecular-weight drug, enoxaparin (Lovenox), was found more effective than unfractionated heparin. (medpagetoday.com)
- SAN ANTONIO, Tex., April 20 -- Enoxaparin (Lovenox), a low molecular-weight heparin, proved more effective than unfractionated heparin for preventing potentially fatal leg and lung clots after acute ischemic stroke, researchers reported. (medpagetoday.com)
- In a head-to-head study of 1,762 stroke patients unable to walk unassisted, enoxaparin was 43% more effective at preventing venous thromboembolism than unfractionated heparin, David G. Sherman, M.D., of the University of Texas here, and colleagues reported in the Apil 21 issue of The Lancet . (medpagetoday.com)
- The results of this study, Dr. Sherman concluded, suggest that for patients with acute ischemic stroke, enoxaparin is preferable to unfractionated heparin for venous thromboembolism prophylaxis in view of its better clinical benefits-to-risk ratio and convenience of once daily administration. (medpagetoday.com)
- Within 48 hours of symptoms, 666 patients were given enoxaparin (40 mg subcutaneously) once daily for 10 days, while 669 got unfractionated heparin (5,000 U subcutaneously) every 12 hours, for 10 days (range for all, six to 14 days). (medpagetoday.com)
- Internal and external bleeding was rare in both groups, although rates for external bleeding were slightly higher in the patients taking enoxaparin. (medpagetoday.com)
- A post-hoc analysis of major subgroups -- diabetes, obesity, previous stroke, age, for example -- showed consistent reductions of venous thromboembolism risk for enoxaparin compared with unfractionated heparin. (medpagetoday.com)
Percutaneous coronary int3
- The current recommended weight-adjusted dosing regimen of unfractionated heparin and target activated clotting time (ACT) in percutaneous coronary intervention (PCI) is based on limited data from the western population, and the applicability in the various Asian ethnic groups remains unknown. (nus.edu.sg)
- The purpose of this trial is to determine whether bivalirudin is non-inferior to unfractionated heparin in patients with stable angina, unstable angina, or non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. (clinicalconnection.com)
- OBJECTIVE: To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective. (uzh.ch)
- They found that the heparan sulfate that this cell line would normally produce was now chemically altered and showed a reactivity that was closer to heparin. (phys.org)
- ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis, Proceedings of the National Academy of Sciences (2020). (phys.org)
- This enzyme catalyses the following chemical reaction endohydrolysis of (1->4)-beta-D-glycosidic bonds of heparan sulfate chains in heparan sulfate proteoglycan Heparanase cleaves the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. (wikipedia.org)
- Heparan sulfate (HS), structurally related to heparin, binds a wide range of proteins of different functionality, taking part in various physiological and pathological processes. (ahajournals.org)
- Additionally, most heparin-binding proteins also bind heparan sulfate (HS). (ahajournals.org)
- CONCLUSIONS--Concomitant intravenous heparin improves coronary patency in patients with alteplase. (bmj.com)
- Conclusions: In conclusion, we demonstrate that protective effect of clinically relevant doses of heparin correlates with its' ability to prolong clotting time and not to inhibition of neutrophil accumulation in the healing of skin flaps. (lu.se)
- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. (emcrit.org)
- Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. (bmj.com)
- OBJECTIVE--To determine whether concomitant treatment with intravenous heparin affects coronary patency and outcome in patients treated with alteplase thrombolysis for acute myocardial infarction. (bmj.com)
- With intravenous heparin, this increase was attenuated, but intravenous heparin did not prevent thrombin generation, as measured by prothrombin fragment 1.2 (F1.2). (onlinejacc.org)
- Although intravenous heparin partly suppresses the increased thrombin activity associated with thrombolysis, it does not inhibit thrombin generation. (onlinejacc.org)
- Top selling expensive blood thinners are only as effective as injections of the blood thinner heparin to treat blood clots, according to researchers on Tuesday. (medindia.net)
- The study found that blood clots reappeared in less than 4 percent of 700 patients whether they were injected with the original heparin or low-molecular weight heparin. (medindia.net)
- Heparin is a prescription medication used to prevent blood clots from forming in people who have certain medical conditions, such as blood vessel, heart, and lung conditions, or who are undergoing certain medical procedures that increase the chance that clots will form, such as open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions. (rxwiki.com)
- Heparin is also used in small amounts to prevent blood clots from forming in catheters (small plastic tubes through which medication can be administered or blood drawn) that are left in veins over a period of time. (rxwiki.com)
- Heparin is used to treat and prevent blood clots caused by certain medical conditions or medical procedures. (cigna.com)
- Heparin is also used before surgery to reduce the risk of blood clots. (cigna.com)
- If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today. (tripdatabase.com)
- The clinical need for such a research program was based on the intial results from studies that showed long-term use of low-molecular-weight heparin among patients with venous thromboembolism was associated with a reduction in cancer mortality. (cmaj.ca)
- However, since significant species dependent differences in transduction characteristics exist, and large animal models are of imminent need for pre-clinical evaluations, we compared the gene transfer efficiency of an AAV2/6 and a heparin-binding site deleted AAV2 (AAV2/dHep) in a porcine model. (ahajournals.org)
- 3 4 Although heparin is widely used as an adjunct to rt-PA treatment in patients with acute myocardial infarction, large clinical trials suggest only a potentially beneficial effect. (bmj.com)
- In fact, there was no apparent difference between unfractionated heparin and no pretreatment at all -- one year survival without experiencing a clinical endpoint (death, recurrent infarction, stroke, or severe bleeding) was about 80% in these two groups, according to Francois Schiele, MD, PhD, of University Hospital Jean Minjoz in Besancon, France. (medpagetoday.com)
- Even with the advent of new anticoagulants, it is anticipated that for the foreseeable future heparin and LMW heparin will remain standard clinical therapy and also a necessary component of successful surgeries and interventional procedures ( 1 ). (frontiersin.org)
- In patients treated with ticagrelor, we found no major differences between bivalirudin and heparin in platelet aggregation or coagulation markers, which is in agreement with the neutral clinical results of the VALIDATE-SWEDEHEART study. (diva-portal.org)
- To investigate the prevalence and clinical correlates of anti-heparin platelet factor 4 antibodies (anti-HPF4) in SLE patients with and without antiphospholipid antibodies (aPL). (bmj.com)
- The diagnosis of HIT is based on clinical features, which can be employed to determine the 4T pre-test probability score, 4 - 6 and laboratory documentation of heparin-dependent antibodies. (haematologica.org)
- Based on the earlier clinical trial and this study, it would be reasonable to consider using fondaparinux as an alternative to heparin to reduce the risk of bleeding and death in patients with this type of heart attack," Creager said. (mentalhelp.net)
- There are several studies with regard to this system, but most of them address only partial aspects such as clinical outcome, agreement between heparin anti-Xa activity and Hepcon HMS results, use in pediatric CPB, protamine-heparin ratios, or determination of unfractionated heparin reversal after CPB. (asahq.org)
- In addition, the HPA Meningococcal Reference Unit provides a national service for species confirmation and grouping/typing of invasive Neisseria meningitidis and offers free nonculture confirmation by using PCR directly from clinical specimens routinely submitted by National Health Service hospital laboratories ( 5 ). (cdc.gov)
- Those patients receiving bivalirudin within 30 days had significantly reduced net clinical adverse events by 24 percent, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent, when compared to a regimen of heparin and GPI. (rxpgnews.com)
- Three aspects of synthetic mimicking polymers are currently focused on: mimicking anionic sulfate domains of heparin, polymerization of sulfated saccharides and sulfation of natural occurring GAGs. (wikipedia.org)
- 8 Due to the poorly regulated supply chain of pharmaceutical heparin, a worldwide distribution of oversulfated chondroitin sulfate (OCSC) contaminated heparin in 2007 was discovered and associated with over 200 deaths in the U.S., adversely affecting the purity and safety of animal-sourced heparins. (rsc.org)
- These are disaccharides carrying one or more sulfate group on a sugar unit. (hmdb.ca)
- GAGs are acidic molecules with numerous sulfate groups and are easily ionized and produce abundant negative ions. (neb.com)
- The lability of the sulfate groups increases as the size of the heparin oligosaccharide increases. (neb.com)
- Data show that for DSCS NPs containing 100 nmol charged glucose sulfate units in DS, up to ~1.5 nmol of monomeric or ~0.75 nmol of dimeric heparin-binding proteins were incorporated without significantly altering the size or zeta potential of the particles. (dovepress.com)
- One group will be randomised to receive taurolidine-citrate catheter lock solution and the other heparin 5000 iu/ml catheter lock solution. (isrctn.com)
- Following adequate treatment, either with or without a new access device (tunneled catheter or subcutaneous port), these patients were randomized to continue Home Parenteral Nutrition using heparin (n = 14) or taurolidine (n = 16) as catheter lock. (nih.gov)
- A separate heparin product is available to use as catheter lock flush. (cigna.com)
Global Heparin Market3
- Technavio's analysts forecast the global heparin market to grow at a CAGR of -4.80% over the period 2014-2019. (medgadget.com)
- This report covers the present scenario and the growth prospects of the global heparin market for the period 2015-2019. (medgadget.com)
- Technavio's report, Global Heparin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. (medgadget.com)
Porcine mucosal heparin1
- 1 2 Several studies have explored the relation between LPL activity and parameters of lipoprotein metabolism (for discussion, see References 3 and 4 3 4 ) by measuring LPL activity in plasma after heparin injection, which is assumed to reflect the LPL available at the endothelial surface, or by studies of LPL activity in tissue biopsies. (ahajournals.org)
- LPL activity in plasma before and after heparin injection are unrelated. (ahajournals.org)
- The first injection of the low-molecular-weight heparin began between twelve and twenty-four hours after the surgery. (nih.gov)
- Injection of low molecular weight heparin caused local skin reactions (pain, itching, swelling) in one study (side effects were not regularly reported in all studies). (cochrane.org)
- What is the most important information I should know about heparin injection? (cigna.com)
- Do not use heparin injection to flush (clean out) an intravenous (IV) catheter, or fatal bleeding could result. (cigna.com)
- What is heparin injection? (cigna.com)
- What should I discuss with my healthcare provider before using heparin injection? (cigna.com)
- Heparin injection is not likely to pass into breast milk, but you should tell your doctor if you are breast-feeding. (cigna.com)
- How should I use heparin injection? (cigna.com)
- You may need to use both the injection and the oral forms of heparin for a short time. (cigna.com)
- What should I avoid while using heparin injection? (cigna.com)
- Heparin is given by injection. (medbroadcast.com)
- 2 Randomized trials were needed to investigate the effectiveness and safety of the long-term use of low-molecular-weight heparin therapy for patients with both venous thromboembolism and cancer. (cmaj.ca)
- 4 The patients were divided into two groups: patients without cancer who required long-term treatment for venous thromboembolism, and patients with cancer who required long-term treatment for venous thromboembolism. (cmaj.ca)
- The purpose of this study was to compare a new mobile compression device with low-molecular-weight heparin with regard to their safety and effectiveness for the prevention of venous thromboembolic disease. (nih.gov)
- The rates of distal and proximal deep venous thrombosis were 3% and 2%, respectively, in the compression group compared with 3% and 1% in the heparin group. (nih.gov)
- Within the twelve-week follow-up period, two events (one deep venous thrombosis and one pulmonary embolus) occurred in one patient in the compression group following negative findings on duplex ultrasonography on the twelfth postoperative day. (nih.gov)
- There was no difference between the groups with regard to the prevalence of venous thromboembolism. (nih.gov)
- When compared with low-molecular-weight heparin, use of the mobile compression device for prophylaxis against venous thromboembolic events following total hip arthroplasty resulted in a significant decrease in major bleeding events. (nih.gov)
- 7 Despite favorable effects of thrombolysis on angiographic, hemodynamic, and scintigraphic measures, the majority of studies comparing thrombolysis with heparin have not demonstrated a reduction in recurrent venous thromboembolism or death 8,9 but have demonstrated an increase in bleeding. (ahajournals.org)
- It has been suggested that the platelet count of patients who are receiving low-molecular-weight Heparin for prophylaxis against deep venous thrombosis be checked at least once prior to discharge 16 . (orthogate.org)
- Results - Age ( P =0.49), sex ( P =0.20), baseline venous infarction ( P =0.73), and predisposing illnesses ( P =0.52) were similar between the thrombolysis and heparin groups. (ahajournals.org)
- The global Peptides and Heparin market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. (rnrmarketresearch.com)
- Global Heparin Active Pharmaceutical Ingredients market size will increase to Million US$ by 2025, from Million US$ in 2017, at a CAGR of during the forecast period. (reportsnreports.com)
- In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Heparin Active Pharmaceutical Ingredients. (reportsnreports.com)
Source of heparin2
- Following the heparin contamination crisis of a decade ago, and recognizing that the majority of world supply of porcine heparin originates from one country ( 3 ), there is interest from regulatory agencies in broadening the source of heparin ( 4 ). (frontiersin.org)
- Is there another source of heparin than mast cells in humans? (bio.net)
Similar to heparin2
- The mysterious substance, which has a chemical makeup similar to heparin, comprises as much as 20 percent of the active ingredient in nine suspect lots produced by Baxter since September, the FDA said Wednesday. (nolan-law.com)
- added, because the tests are not designed for that purpose.The FDA in its press conference Wednesday said conventional tests performed by Baxter and Scientific Protein did not show any variation because the contaminant is so similar to heparin. (nolan-law.com)
Known whether heparin2
- Observational Study of Need for Thrombolytic Therapy and Incidence of Bacteremia using Taurolidine-Citrate-Heparin, Taurolidine-Citrate and Heparin Catheter Locks in Patients Treated with Hemodialysis. (biomedsearch.com)
- Studies suggest that thrombin activity increases after thrombolytic therapy [1-and that heparin can lessen this increase . (onlinejacc.org)
- Hemorrhagic complications, using the definitions endorsed by the International Society on Thrombosis and Hemostasis 6 and developed by Hull and coworkers in 1982, 7 occurred less often in the low-molecular-weight heparin group, largely because of a lower incidence of minor bleeding. (cmaj.ca)
- Even with the use of pneumatic compression devices, the incidence of DVT has been reported to be 32% in these patients, making prophylactic heparin therapy desirable. (thejns.org)
- Both unfractionated and low-molecular-weight heparin have been shown to reduce the incidence of DVT consistently by 40 to 50% in neurosurgical patients. (thejns.org)
- The addition of unfractionated heparin to thrombolytic treatment resulted in a slightly higher incidence of bleeding, but no differences in the incidence of haemorrhagic strokes were reported. (bmj.com)
- There were non-significant trends towards a smaller enzymatic infarct size and a higher incidence of bleeding complications in the group treated with heparin. (bmj.com)
- CX-01 appeared to be well tolerated with no significant increased incidence of bleeding in either group receiving CX-01. (cancernetwork.com)
- RESULTS--Coronary patency (TIMI grades 2 or 3) was 83.4% in the heparin group and 74.7% in the group given placebo for heparin. (bmj.com)
- A formulation of 1.35% Taurolidine in 4% citrate (TC) is associated with a greater need for thrombolysis to maintain catheter patency than 5000 U/ml heparin. (biomedsearch.com)
- Addition of 500 U/ml heparin to TC reduces the need for thrombolysis without increasing bacteremia and may achieve patency comparable to heparin 5000 U/ml. (biomedsearch.com)
- After alteplase and heparin therapy, infarct-related artery patency more often occurs in patients with longer activated partial thromboplastin times (aPTT) [5, . (onlinejacc.org)
- These articles are reviewed below in addition to the FRISC trial (the largest study comparing low molecular-weight heparin vs. placebo). (emcrit.org)
- Patients were allocated to abciximab and low-dose heparin ( n = 935), abciximab and standard-dose heparin ( n = 918), or placebo and standard-dose heparin ( n = 939). (acpjc.org)
- Were patients in the placebo groups in these studies put at an unfair disadvantage? (acpjc.org)
- The first group of patients will receive heparin intravenously at the beginning of 2500 UI bolus intravenously, followed by intravenous pump 1000 UI / h (18-20 IU / kg / hr) to reach 2-2.5 times the baseline aPTT. (clinicaltrials.gov)
- 9-13 Evidence from subsets of patients in the SCATI and GISSI-2 trials suggests that the administration of high dose subcutaneous heparin results in better survival than when no heparin is given (mortality 4.5% among patients receiving heparin v 8.8% among patients who did not receive heparin). (bmj.com)
- Intravenous (IV) unfractionated heparin (UFH) is widely used in the management of patients with acute coronary syndromes, particularly those with unstable angina and non-ST segment elevation myocardial infarction (MI) (1-4) in whom atheromatous plaque disruption and intracoronary thrombosis commonly co-exist (5) . (onlinejacc.org)
- Although these studies have provided valuable information, heparin/HS-binding proteins differ widely in structure. (ahajournals.org)
- In this substudy of VALIDATE-SWEDEHEART trial, 103 patients pretreated with ticagrelor were randomized before PPCI to heparin or bivalirudin. (diva-portal.org)
- ADP-induced PR did not significantly differ between groups over time (heparin vs bivalirudin, AUC 73 (62) vs 74 (68), p = 0.74, 32 (42) vs 43 (51), p = 0.38, 15 (15) vs 19 (15), p = 0.29, before, 1 and 12 h after PPCI). (diva-portal.org)
- F1 + 2 increased in both groups but the rise was numerically higher with bivalirudin (170 (85) to 213 (126) pmol/L vs 168 (118) to 191 (103) pmol/L). At 12 h, a comparable significant increase in thrombin generation was observed in both groups. (diva-portal.org)
- Bivalirudin during primary angioplasty better than heparin and glycoprotein IIb/IIIa inhibitors (GPI). (rxpgnews.com)
- In the landmark global trial, bivalirudin was compared to heparin plus GPI in more than 3,600 patients with ST-segment (a specific electrocardiogram wave) elevation myocardial infarction (STEMI), the most severe form of heart attack. (rxpgnews.com)
- A total of 3,602 patients undergoing angioplasty were randomly assigned to receive either bivalirudin with provisional use of GPI or heparin plus GPI. (rxpgnews.com)
- The HORIZONS-AMI data show that using bivalirudin instead of heparin with a GPI during angioplasty increases survival in heart attack patients who are at high risk for death or disability," Dr. Stone said. (rxpgnews.com)
- Only 7.2 percent of patients in the bivalirudin group received provisional GPI. (rxpgnews.com)
- Bivalirudin has previously been shown to result in less bleeding and similar rates of composite ischemia compared to heparin plus GPI in patients undergoing angioplasty for stable angina, unstable angina and non-ST-elevation myocardial infarction (NSTEMI). (rxpgnews.com)
- In conclusion, the recommended weight-adjusted heparin-dosing regimen in PCI derived from the western population is equally applicable to the Asian patients. (nus.edu.sg)
- A potentially important difference between the PREVAIL study and many of the previous trials was the choice of the unfractionated heparin dosing regimen. (medpagetoday.com)
- Because this study did not compare the unfractionated heparin thrice-daily regimen, the risk reduction for that prophylactic regimen was difficult to discern. (medpagetoday.com)
- In the current investigation, we compared heparin management using the Hepcon HMS with an ACT regimen by assessing key parameters of coagulation and inflammation in 200 patients undergoing elective standard cardiac surgery. (asahq.org)
- 5 6 Although the results of these non-randomised comparisons have to be interpreted with caution, most cardiologists have adopted the use of heparin as an adjunct to rt-PA thrombolysis in patients with acute myocardial infarction. (bmj.com)
- Our aim was to determine whether addition of 500 Units/ml of heparin to TC reduces the need for thrombolysis. (biomedsearch.com)
- Hemorrhagic complications were 10% (n=2) in the thrombolysis group (subdural hematoma, retroperitoneal hemorrhage) and none in the heparin group ( P =0.49). (ahajournals.org)
- All patients in the thrombolysis group were from Dallas (n=18) and Houston (n=2). (ahajournals.org)
- The purpose of this study was to determine the mechanistic basis for thrombin generation and increased prothrombotic potential after the abrupt cessation of intravenous (IV) unfractionated heparin among patients with acute coronary syndromes. (onlinejacc.org)
- Fibrinopeptide A (FPA), a marker of thrombin activity toward fibrinogen, was elevated at baseline (12.3 ng/ml) and increased to 18.4 ng/ml by 90 min after streptokinase and subcutaneous heparin treatment. (onlinejacc.org)
- Macromolecular ternary complexes (formed by HIT antibodies, PF4-tetramers and heparin chains) are able to activate platelets, endothelial cells and monocytes, leading to excessive in vivo thrombin generation. (haematologica.org)
- 1,2 In 1973, Rosenberg and Damus suggested that heparin binds the protease inhibitor antithrombin (AT), causing a conformational change within AT, accelerating its reaction with the protease thrombin and the formation of an active complex between protease and inhibitor. (ahajournals.org)
- 6 Among the reasons that make this task so difficult is that heparin is a polydisperse polysaccharide with a heterogeneous saccharide sequence that binds a large number of proteins. (ahajournals.org)
- Heparin is a linear, polydisperse polysaccharide consisting of repeating units of 1→4-linked pyranosyluronic acid and 2-amino-2-deoxyglucopyranose (glucosamine) residues. (ahajournals.org)
- In this study, a double network hydrogel of a natural polysaccharide gellan gum (GG) hydrogel and a synthetic hydrogel poloxamer-heparin (PoH) hydrogel (PoH/GG DNH) is introduced to complement disadvantages of each hydrogel and improve the microenvironment for cell delivery. (uminho.pt)
- Anti-platelet factor 4/heparin-antibodies were measured with three immunoassays (ID-H/PF4-PaGIA, Asserachrom-HPIA, and GTI-PF4) and their functional relevance was assessed by a two-point heparin-induced platelet aggregation test. (haematologica.org)
- Results Among 1,291 patients, 96 (7.4%) had a positive heparin-induced platelet aggregation-test: 7 of 859 (0.8%) with a low, 50 of 358 (14.0%) with an intermediate, and 39 of 74 (52.7%) with a high 4T-score. (haematologica.org)
- Mortality was the same in both groups. (bmj.com)
- In patients who are having percutaneous coronary angioplasty (PTCA), will abciximab and adjusted heparin reduce ischemic morbidity and mortality at 1 year? (acpjc.org)
- the groups did not differ for all-cause mortality (1.7% and 1.8% vs 2.6%, P = 0.2). (acpjc.org)
- Low-molecular-weight heparin and mortality in acutely ill medical patients. (bmj.com)
- HTF MI published a new industry research that focuses on Low Molecular Weight Heparin (LMWHs) market and delivers in-depth market analysis and future prospects of Asia-Pacific Low Molecular Weight Heparin (LMWHs) market. (medgadget.com)
- The research covers the current market size of the Asia-Pacific Low Molecular Weight Heparin (LMWHs) market and its growth rates based on 5 year history data along with company profile of key players/manufacturers. (medgadget.com)
- The in-depth information by segments of Low Molecular Weight Heparin (LMWHs) market helps monitor future profitability & to make critical decisions for growth. (medgadget.com)
- The information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the Asia-Pacific Low Molecular Weight Heparin (LMWHs) Market. (medgadget.com)
- Following would be the Chapters to display the Asia-Pacific Low Molecular Weight Heparin (LMWHs) market. (medgadget.com)
- In a multicenter, double-blind, randomized, controlled trial, TSC 30% was compared with unfractionated heparin 5000 U/ml for prevention of catheter-related infections, thrombosis, and bleeding complications. (asnjournals.org)
- outbreaks, botulism, events from 105 states parties, including 24 events from Escherichia coli O157:H7 infections, Guillain-Barré syn- drome, contaminated heparin, Lassa fever, an oil spill, and Author affi liations: Centers for Disease Control and Prevention, typhoid fever. (cdc.gov)
- Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the antithrombotic therapy in acute coronary syndromes study group). (emcrit.org)
- A dosing strategy of abbreviated IV weaning attenuates but does not prevent heparin rebound among patients with acute coronary syndromes. (onlinejacc.org)
- Low-molecular-weight heparin for the treatment of acute ischemic stroke. (acpjc.org)